Trial reportDrug design, development and therapy2026
The Effect of Food on the Pharmacokinetics and Gastrointestinal Tolerability of Bersiporocin, a Novel Oral Prolyl-tRNA-Synthetase Inhibitor.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Methodological and Outcome Interpretation Concerns for the Food-Effect Study of Bersiporocin [Letter].Drug design, development and therapy · 2026Article
- Authors' Reply to "Methodological and Outcome Interpretation Concerns for the Food-Effect Study of Bersiporocin" [Response to Letter].Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Bersiporocin is a first-in-class prolyl-tRNA-synthetase inhibitor under clinical development for the treatment of idiopathic pulmonary fibrosis. In a prior first-in-human study, the incidence of gastrointestinal (GI) adverse events (AEs) differed across prandial conditions. This study aimed to evaluate the effect of food on the pharmacokinetics (PKs) and safety profile of bersiporocin. Patients and Methods: This randomized, open-label, single-dose, three-period crossover study enrolled 36 healthy Korean participants. Each participant received a single oral dose of bersiporocin 200 mg under three conditions: fasted (A), 30 minutes after a high-fat meal (B), and 2 hours after a high-fat meal (C), with a 7-day washout between periods. Plasma concentrations of bersiporocin and its active metabolite M8 were quantified using a validated LC-MS/MS assay, and PK parameters were determined by non-compartmental analysis. Safety was evaluated by monitoring AEs, clinical laboratory tests, vital signs, and electrocardiograms. Results: A high-fat meal delayed the absorption of bersiporocin and M8. The median T Conclusion: A high-fat meal delayed the oral absorption rate of bersiporocin but did not have a clinically significant effect on systemic exposure to bersiporocin or M8. Given the increased incidence of GI AEs under early postprandial conditions, administration under fasted conditions or at least 2 hours postprandially may be appropriate for future clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.